Swiss National Bank bought a new position in Calithera Biosciences Inc (NASDAQ:CALA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 45,300 shares of the biotechnology company’s stock, valued at approximately $378,000. Swiss National Bank owned approximately 0.13% of Calithera Biosciences at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. California State Teachers Retirement System acquired a new position in shares of Calithera Biosciences in the 2nd quarter worth approximately $806,000. Vanguard Group Inc. grew its position in shares of Calithera Biosciences by 29.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock worth $17,813,000 after acquiring an additional 274,510 shares in the last quarter. American Century Companies Inc. grew its position in shares of Calithera Biosciences by 272.8% in the 3rd quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock worth $6,690,000 after acquiring an additional 310,806 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Calithera Biosciences by 21,557.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,390 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 23,282 shares in the last quarter. Finally, State Street Corp grew its position in shares of Calithera Biosciences by 5,802.1% in the 2nd quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock worth $19,370,000 after acquiring an additional 1,282,275 shares in the last quarter. Institutional investors own 68.91% of the company’s stock.
Several brokerages have recently commented on CALA. BidaskClub lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 18th. ValuEngine lowered Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research lowered Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Citigroup upgraded Calithera Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $6.95 to $14.00 in a research report on Friday, February 16th. Three analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $16.67.
Calithera Biosciences Inc (NASDAQ:CALA) opened at $7.15 on Friday. Calithera Biosciences Inc has a 12-month low of $6.57 and a 12-month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.09). Calithera Biosciences had a negative net margin of 107.21% and a negative return on equity of 17.49%. The company had revenue of $7.24 million for the quarter, compared to analyst estimates of $7.28 million. During the same quarter in the prior year, the firm earned ($0.45) EPS. research analysts forecast that Calithera Biosciences Inc will post -1.05 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “45,300 Shares in Calithera Biosciences Inc (CALA) Acquired by Swiss National Bank” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/17/45300-shares-in-calithera-biosciences-inc-cala-acquired-by-swiss-national-bank.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.